Hanwha's Philly Shipyard can build nuclear submarine for US Navy, executive says
Hanwha's Philly Shipyard can build nuclear submarine for US Navy, executive says
BTC
ETH
USDT
XRP
USDC
SOL
TRX
FIGR_HELOC
DOGE
WBT
USDS
HYPE
LEO
ADA
BTC
ETH
USDT
XRP
USDC
SOL
TRX
FIGR_HELOC
DOGE
WBT
USDS
HYPE
LEO
ADA
BTC
ETH
USDT
XRP
USDC
SOL
TRX
FIGR_HELOC
DOGE
WBT
USDS
HYPE
LEO
ADA
BTC
ETH
USDT
XRP
USDC
SOL
TRX
FIGR_HELOC
DOGE
WBT
USDS
HYPE
LEO
ADA
Bitcoin bulls avoided a correction as US markets opened, but analysis warned that Strategy was responsible for much of the latest BTC price strength.
Most popular articles this week
Latest news from global stock markets, tech giants, and financial sectors
Browse ArticlesBitcoin, Ethereum, altcoins, DeFi, NFTs, and blockchain technology
Browse ArticlesGold, silver, oil, natural gas, and other precious commodities
Browse Articles
Hanwha's Philly Shipyard can build nuclear submarine for US Navy, executive says
The seasonal rally typically runs through the first two trading days of the new year.
Notre Dame recently decided to pass up an invitation to play in the Pop-Tarts Bowl.
For the S&P 500, Dec. 26 has historically been the most reliably positive day of the year.
Engaging one of the worldâEUR(TM)s most repressive regimes, Trump envoy bonded with Belarusian dictator over Zepbound and obtained the release of hundreds...
A shaky economy, wider adoption of weight-loss drugs, and changing tastes seem to conspire against some food makers.
Lilly, Novo lock horns in India's obesity drug race
Rain crypto has gained 125% over the past 30 days, pushing its market cap to over $2.7B, making it one of Arbitrum's largest coins. This rise follows a spe...
Can Fite Biopharma stock tumbles after announcing 1-for-3,000 reverse split
Financial worries have gradually taken over as employees' biggest concerns since inflation spiked, the job market stalled and the rise of AI threatens to d...
The growing use of weight-loss drugs is one factor behind the decline in alcohol consumption.
Relief rally underway in Novo Nordisk after a difficult year for the stock which saw it lose ground to arch-competitor Eli Lilly.